BMJ Open

Fatigue outcomes following COVID-19: a systematic review and meta-analysis

Kim Poole-Wright [1], Ismail Guennouni [2], Olivia Sterry,[1] Rachael A Evans [3], Fiona Gaughran [4,5] Trudie Chalder [1]

¹Psychological Medicine, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK
²Experimental Psychology, University College London, London, UK
³Department of Respiratory Sciences, University of Leicester, Leicester, UK
⁴Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK
⁵National Psychosis Service, South London and Maudsley NHS Foundation Trust, London, UK

Correspondence to
Professor Trudie Chalder;
trudie.chalder@kcl.ac.uk

ABSTRACT

Objectives Fatigue is a pervasive clinical symptom in coronaviruses and may continue beyond the acute phase, lasting for several months or years. This systematic review and meta-analysis aimed to incorporate the current evidence for postinfection fatigue among survivors of SARS-CoV-2 and investigate associated factors.

Methods Embase, PsyINFO, Medline, CINAHL, CDSR, Open Grey, BioRxiv and MedRxiv were systematically searched from January 2019 to December 2021. Eligible records included all study designs in English. Outcomes were fatigue or vitality in adults with a confirmed diagnosis of SARS-CoV-2 measured at >30 days post infection. Non-confirmed cases were excluded. JBI risk of bias was assessed by three reviewers. Random effects model was used for the pooled proportion with 95% CIs. A mixed effects meta-regression of 35 prospective articles calculated change in fatigue overtime. Subgroup analyses explored specific group characteristics of study methodology. Heterogeneity was assessed using Cochran's Q and I^2 statistic. Egger's tests for publication bias.

Results Database searches returned 14 262 records. Following deduplication and screening, 178 records were identified. 147 (n=48 466 participants) were included for the meta-analyses. Pooled prevalence was 41% (95% CI: 37% to 45%, k=147, I^2=98%). Fatigue significantly reduced over time (−0.057, 95% CI: −107 to −0.008, k=35, I^2=99.3%, p=0.05). A higher proportion of fatigue was found in studies using a valid scale (51%, 95% CI: 43% to 58%, k=36, I^2=96.2%, p=0.004). No significant difference was found for fatigue by study design (p=0.272). Egger's test indicated publication bias for all analyses except valid scales. Quality assessments indicated 4% at low risk of bias, 78% at moderate risk and 18% at high risk. Frequently reported associations were female gender, age, physical functioning, breathlessness and psychological distress.

Conclusion This study revealed that a significant proportion of survivors experienced fatigue following SARS-CoV-2 and their fatigue reduced overtime. Non-modifiable factors and psychological morbidity may contribute to ongoing fatigue and impede recovery.

PROSPERO registration number CRD42020201247.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This review and meta-analysis was conducted using a significant sample size from a comprehensive search of the literature, including only confirmed cases.
⇒ Substantial unexplained heterogeneity between studies limits generalisability of our findings.
⇒ Only one reviewer screened and extracted the data from each study leaving the potential for missing articles and selection errors.
⇒ Outcome measures of fatigue were unvalidated in the majority of studies, limiting confidence in our estimates.
⇒ Total point prevalence was likely impacted by the predominance of hospitalised patients with potentially more severe disease.

INTRODUCTION

Fatigue may be characterised as tiredness or exhaustion as a result of physical or mental exertion or as a result of an illness or disease. The experience of fatigue is common and is usually short-lived but, for a small number of people, it can become long-lasting, associated with a number of impairments in daily living and quality of life.[1] It is one of the most common presenting symptoms of coronaviruses.[2] The current pandemic has also revealed a considerable burden of lasting symptoms,[3–12] with approximately one in four people experiencing fatigue by one estimate.[13] Systematic reviews indicate a pooled prevalence of post-COVID-19 fatigue to vary among 45%,[14] 52%[15] and 64%.[16] In previous epidemics, fatigue was enduring. In a follow-up of 90 SARS survivors 30 months post illness, for instance, 1 study found significantly lower vitality scores compared with Hong Kong population norms.[17] A small study of Middle East respiratory syndrome patients revealed that 32.7% had clinically relevant chronic fatigue, according to their Fatigue Severity Scale (FSS) scores, at 18 months' follow-up.[18] Likewise, for a considerable number of patients with COVID-19, tiredness symptoms extend beyond 3 months and represent a larger burden of postinfection symptomology.[19–41] A large study of 1142 hospitalised patients found that 61% had fatigue 7 months post COVID-19.[42] Similarly, those who perceived themselves as

experiencing 'poor recovery' had lower vitality on the 15D instrument, compared with those making a 'full recovery' (p<0.001) 1 year post illness.[43]

More severe disease, associated with being hospitalised or intensive care unit (ICU) admission, has been related to postillness fatigue.[44–51] In a small cohort of 55 people, 30 days post discharge for COVID-19, each additional day of hospitalisation increased fatigue by 1.2.[52] Apart from hospitalised patients, among non-hospitalised or those treated for milder disease, fatigue is persistent.[53–61] In 359 patients, 63.4% reported significant fatigue up to 12 months post infection and were more likely than admitted patients to require referral for fatigue symptomology.[62]

Determinants of postillness fatigue include female gender[63–66] and older age, although the latter relationship was not consistent. Being over 50 years was associated with fatigue severity in some studies,[52 67 68] but not in others.[69 70] Exercise impairments are a common feature of post-COVID-19 sequelae.[71–77] Poorer performance on the 6 min walk test (6MWT) was associated with fatigue and lower vitality at 6 months despite no concomitant impairments in pulmonary functions.[78] Indeed, impairments in lung functions have not thus far fully explained worse fatigue in COVID-19.[78–81] Nevertheless, patients often report persistent dyspnoea, which was consistently related to their fatigue,[82–85] suggestive of multidimensional functional consequences. For instance, quality of life,[86] functional status[87] and an increased risk for postinfection healthcare needs[88] were all related to fatigue.

Anxiety, post-traumatic stress and depressive symptoms are prevalent in survivors of respiratory viral infections.[85 89–94] A meta-analysis of 36 COVID-19 articles found high rates of anxiety (29%) and depressive symptoms (23%) 4–12 weeks post illness.[95] The relationship between mental health outcomes and fatigue is consistent among convalescing patients with COVID-19. Depressive symptoms, for example, were associated with lower vitality[96] and fatigue.[79 97] In a retrospective study of 55 patients, baseline anxiety was related to higher fatigue 30 days after hospitalisation.[52] Moreover, these relationships can be present at 12 months' follow-up. Mazza et al[98] found depression (r=0.56, q=0.05) and post-traumatic stress disorder (PTSD) (r=0.52, q=0.05) were related to fatigue severity in 402 post-COVID-19 patients. Neuropsychiatric symptoms, comprising anxiety, mood swings, irritability and depression and others, predicted chronic fatigue 9 months later for those with mild/moderate disease (p=0.01).[99]

Summary and aims

For the majority of patients, acute fatigue diminishes during the course of a virus, but current evidence suggests some experience longer lasting symptoms, and these affect functional and psychological recovery. Meta-analyses have focused on postacute sequelae of COVID-19 or clusters of symptoms, and therefore fewer studies have investigated solely fatigue outcomes. Moreover, a proportion of these reviews were narrative in design, which did not provide a pooled estimate for fatigue. Furthermore, fatigue is reported as the most prominent factor of post-infection symptomology indicative of its importance in understanding recovery. Therefore, the objectives of this systematic review were to (a) investigate the prevalence of persistent fatigue among survivors of COVID-19, (b) integrate the findings by conducting a meta-analysis and (c) investigate current evidence for factors associated with fatigue outcomes in this context.

METHODS

Search strategy

The protocol and PICO framework for this study (online supplemental file 1) was developed using the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA).[100] Embase, PsyINFO, Medline, CINAHL, Cochrane Database of Systematic Reviews, Open Grey, MedRxiv and BioRxiv were systematically searched from January 2019 to 31 December 2021. Search terms: severe acute respiratory syndrome or severe acute respiratory adj2 syndrome or coronavirus or corona virus or corona adj1 virus or COVID-19 or COVID-19 or SARS-CoV-2 or SARS-CoV or SARSCOV2 or SARSCOV-2 or nCoV-2 or 2019-nCoV or nCoV19 or nCoV2 or COVID-19 or COVID-19 or covid and 'chronic fatigue' or fatigue or tired* or exhaust* or quality adj2 life or QoL or health related quality) adj2 life or HRQoL. We incorporated 'health-related quality of life' into our search terms in order to capture 'vitality', which we used as proxy for fatigue. Reference lists of the review studies were manually searched for additional articles. Full search protocols for each database are available in online supplemental file 2. Duplicate references were removed electronically and imported into Rayyan[101] for screening and inclusion decisions.

Inclusion and exclusion criteria

Included were original articles with primary data, published in English between January 2019 and December 2021. Adult patients (≥18 years) must have had a diagnosis of SARS-CoV-2 confirmed by RT-PCR, IgM/IgG serology or clinical assessment (eg, X-ray, CT scan of the chest). 'Probable' or self-reported cases were excluded. All study designs were incorporated except qualitative and case reports. Main outcomes were fatigue/vitality reported as 'postdischarge', 'posthospitalisation', 'postacute', 'postillness' or 'postonset'. Outcomes were included if measured at a median/mean time of >30 days post infection as defined. All associations with fatigue/vitality were included if reported/quantified (eg, anxiety, dyspnoea). We excluded pandemic fatigue (defined as 'worn out' by pandemic warnings, government safety instructions, media coverage or compliance requirements), healthcare worker fatigue in the context of their work (eg, burnout, compassion fatigue), comorbid physical disease or pregnant populations. We excluded 'muscle fatigue', 'leg fatigue' and fatigue combined with 'malaise' or 'muscle weakness'. Protocols, vaccination studies,

Figure 1 Preferred Reporting Items for Systematic Review and Meta-Analysis 2020 flow diagram.

newspaper articles, conference papers, commentaries, opinions or editorials were also omitted.

Data extraction

Titles and abstracts were screened by one reviewer (KP-W). Full texts were screened by KP-W. A data spreadsheet was created to record extracted data from the included studies. Spreadsheet variables were citation, population, sample size, control group, location, virus type and diagnostic method, follow-up period, study design, inclusion/exclusion criteria, objectives, outcome variable of interest (eg, fatigue, vitality), associated variables (eg, PTSD, dyspnoea), scales/measures employed, results, power calculation (Y/N). The senior researcher (TC) reviewed 10% of the final included studies. Discrepancies were resolved via discussion and consensus. A PRISMA flow diagram is available in figure 1.

Quality assessments

Risk of bias was assessed by the JBI Critical Appraisal Tools.[102] Items related to bias included 'Were confounding

factors identified?', which demanded a 'yes', 'no', 'unclear' or 'not applicable'. An overall assessment was made by assigning a grade of low quality, moderate quality or good quality. Three researchers (KP-W, OS and TC) independently graded 73%, 14% and 13% each of the total articles and, for the purposes of inter-rater estimation, researchers graded the same 10% of the articles. Inter-rater agreement was assessed by Fleiss' kappa, which indicated moderate agreement (k=0.534, p=0.004).

Statistical analysis

We computed pooled mean prevalence for fatigue outcomes with 95% CIs using a random effects model as high heterogeneity was anticipated. A number of studies investigated fatigue across multiple time points. Therefore, in order to maintain the independence of observations for the pooled prevalence, we selected 1 time point with accompanying prevalence from each study using 1 of the 3 methods: (a) fatigue reported at the stated mean/median time of the follow-up assessment, for example,

127 days post illness, (b) fatigue at the 3-month follow-up (being the mode for all 147 studies) or (c) for studies investigating fatigue>4 months, we selected the shortest time point. Studies with missing data were excluded from analyses. Where studies investigated both 'fatigue' and chronic fatigue syndrome (CFS) outcomes, we incorporated the 'fatigue' data only. This was because a confirmed diagnosis of CFS could not be established. To determine the trend for fatigue, 35 prospective studies, with available data for >2 follow-up times, were included in a meta-regression using the mixed effects framework for meta-analyses developed by Sera *et al*.[103] Meta-regression coefficients were estimated using a restricted maximum likelihood estimator. To determine the proportion of fatigued participants by study design, and to increase the power, we categorised studies into two categories: 'cross-sectional' and 'prospective'. The latter included longitudinal and retrospective designs. The cross-sectional category comprised the remaining designs. Two categories were used to investigate proportions for 'ongoing symptomatic COVID-19' (1–3 months) and 'post-COVID-19 syndrome' (>3 months) following The National Institute for Health and Care Excellence guidelines (nice. org.uk). The robustness of the main pooled prevalence was checked by controlling for the presence of outliers. Studies with 95% CIs falling outside the 95% CI of the total pooled effect were defined as 'outliers'. Sensitivity analysis was performed on the mean pooled prevalence by excluding high risk of bias studies and unpublished studies. To investigate the proportion of fatigued by scale, two categories were used: (a) studies with a valid fatigue scale and (b) studies without a valid fatigue scale. Meta-analyses were conducted using R Studio, V.1.3.1073[104] using packages meta, metafor, dmetar, metareg, mixmeta and irr. Heterogeneity was assessed using Cochran Q statistic. We obtained the I^2 statistic with the degree of heterogeneity categorised as 'not important' (0%–40%), 'moderate' (30%–60%), 'substantial' (50%–90%) and 'considerable' (75%–100%).[105] We conducted Egger's tests and produced funnel plots to explore potential publication bias for all proportional analyses. For 'vitality' outcomes, lack of comparable controls and missing data precluded a means difference analysis.

Patient and public involvement

No patient was involved in this study.

RESULTS

Search results

A total of 14 262 articles were identified using the database search protocols. Following the removal of duplicates, 13 210 articles remained for title and abstract screening. Of these, a total of 3222 were selected for full-text screening producing a final total of 178 studies and 22 systematic reviews. We identified 147 as eligible for a quantitative analysis. A summary of the 147 included articles is available in online supplemental table 1. The

studies are tabulated according to categorical and continuous fatigue outcome measures. Summary table of systematic reviews is available in online supplemental file 3.

Study characteristics

A total of 178 articles comprising 48 466 participants and 22 systematic reviews were included.[13–16 91 95 106–121] A total of 14 (8%) were preprints, 30 (17%) used a fatigue scale and 27 (15%) used a validated measure with a fatigue item(s). A total of 13 (7%) used the 'vitality' subscale of the 36-Item Short Form Survey (SF-36) and 108 (61%) employed a questionnaire, interview or health records. The most common countries were Italy with 25 studies and the USA with 23 studies. The UK had 19 studies and China had 14 studies. Spain had 12 and France had 9 studies. Germany had eight studies and Switzerland had seven studies. The Netherlands and Turkey had six studies each and India had five studies. Iran had four studies. Bangladesh, Denmark, Egypt and Pakistan had three studies each. Brazil, Chile, Israel, Mexico, Norway and Sweden all had two studies. Austria, Australia, Belgium, Canada, Colombia, Finland, Ireland, Hungary, Japan, Lithuania, Mexico, Nepal, Poland, Russia, Saudi Arabia and Zambia each had one study. There were 80 prospective and 11 retrospective cohort deigns. Six longitudinal studies, 29 cross-sectional, 8 case–controls, 5 case series, 36 cohorts, 3 randomised-controlled trials and 22 systematic reviews. The most frequent follow-up times were 3 months (46 studies), 6 months (22 studies), 1 month (20 studies), 12 months (12 studies) and 2 months (12 studies). All other time points had <8 studies. JBI quality assessments resulted in most studies receiving a moderate rating. Full ratings are available in online supplemental file 4. In summary, 32 were assigned a 'high' risk of bias, 139 received a 'moderate' risk assessment and only 7 were considered 'low' risk. Lower grades were assigned for selection bias, lack of adequate control groups, small samples, study design and methodological bias (employment of unvalidated/unreliable scales).

Meta-analyses

A total of 48 466 participants were included for the meta-analysis of proportions using a random effects model. A pooled prevalence from 147 studies was found to be 41% (95% CI: 37% to 45%, I^2=98%). A forest plot of this analysis is available in figure 2. Fatigue was present between 1 month and 1 year post infection with a median time of 3 months (IQR=2–6). An Egger's test was conducted to assess possible publication bias for our proportional analysis. The results indicated funnel plot asymmetry (bias=3.35, p=0.001) (online supplemental file 5).

To explore potential origins of heterogeneity and to test the robustness of our pooled prevalence, outliers were controlled for. A 1% difference was found once n=84 outlier studies were removed; 42% (95% CI: 40% to 45%, I^2=67%), although heterogeneity was reduced to 'substantial'. Given the range of postinfection assessment periods, the effect of time on fatigue was investigated by a linear

Figure 2 Forest plot for proportion of fatigued.

Table 1 Results of linear mixed-effect meta-regression of time and hospitalisation

Parameter	Estimate	SE	AIC	P value	95% CI Lower	Upper
Months	−0.0577	0.0252	501.933	0.05	−0.1070	−0.0084
Hospitalisation	−0.0871	0.1088	–	0.445	−0.3013	0.1326
Months: hospitalised	0.0324	0.0674	505.680	0.630	−0.0997	0.1645

AIC, Akaike information criterion.

mixed effects model meta-regression. The outcome variable was the proportion of individuals reporting fatigue, with 'months' (number of months since infection) and 'hospitalisation' (whether someone was hospitalised) as predictors. A total of 35 studies with available fatigue data and multiple time points (≥2 follow-ups) were included. We found an effect of time, with the proportion of fatigued participants decreasing by 5.7% per month (95% CI: 1% to 10%, p=0.05). There was no effect of hospitalisation and no interaction between hospitalisation and time (table 1).

We conducted two subgroup analyses to explore the origins of heterogeneity arising from study methodology and investigate between group differences. No significant difference in fatigue was found between n=67 cross-sectional studies (44%, CI: 38% to 50%, I^2=97.6%) and n=80 prospective studies (39%, CI: 33% to 45%, I^2=98%), p=0.272.

A higher proportion of fatigued participants was found in n=36 studies using a scale (51%, 95% CI: 43% to 58%, I^2=96.2%) compared with n=111 studies using an unvalidated questionnaire (38%, 95% CI: 33% to 43%, I^2=98%), p=0.004. To assess fatigue occurring at (a) 1–3 months ('ongoing symptomatic COVID-19') and (b) >3 months ('post-COVID-19 syndrome'), two random effects subgroup analyses were conducted. Between 1 and 3 months, the proportion of fatigued was 41% (95% CI: 36% to 47%, k=86, I^2=98.3%). At >3 months, the proportion was 41% (95% CI: 34% to 48%, k=61, I^2=97.4%). Sensitivity analysis was performed by excluding n=30 quality assessments (graded 'low') and removing unpublished results from the main analysis (n=8). Results found the pooled prevalence to be 40% (95% CI: 36% to 45%, I^2=98.3%) and 41% (95% CI: 37% to 46%, k=139, I^2=98%), respectively, indicating little impact on the main results. Egger's tests indicated publication bias for both time categories and sensitivity. Plots are available in online supplemental files 6–15.

Factors associated with fatigue

Not all studies investigated or reported factors associated with fatigue. For some, the available data for each risk factor were too few to conduct a quantified analysis. Studies also used diverse outcome measures or non-validated scales. In addition, some risk factors were reported but not accompanied by quantified data making comparisons between studies problematic. Consequently, reported associations were arranged in tabular form illustrating the direction of the association with fatigue (table 2). A positive symbol (+) indicated a positive association, a negative symbol (−) indicated a negative association and a zero (0) indicated no significant association between the investigated variable and fatigue.[122] The follow up time point in the prospective cohort designs is shown in brackets. Where a risk factor was examined with another (eg, ICU admission with age), one set of results was included. Full details of the associations are available in online supplemental file 16.

Non-modifiable factors

Older age was reported in 30 studies with mixed results. A total of 6 reported an association with or an increased likelihood of fatigue (OR=1.02) in participants>50.[52 66–68 123 124] Two reported higher fatigue in >60 year olds[125] and >40 year olds.[83] Some, however, reported that younger age related to fatigue[126–129] or no difference in fatigue severity between <65 and >65 year olds.[130] The remaining 17 studies did not find a relationship to fatigue.[69 70 79 80 84 85 96 98 99 131–138] However, studies reporting non-significant results had small-to-modest sample sizes and were therefore potentially underpowered. Gender was investigated by 46 studies. A total of 30 studies reported a significant association with fatigue. More women were fatigued,[42 52 63–66 68 96 98 99 123 125 128 130 133 136 139–152] they (54.3%) reported more severe/moderate fatigue than men (29.6%)[86 129] and had significantly lower vitality scores (M=81.80) compared with men (M=83.25).[124] However, 16 used an unvalidated instrument potentially affecting results. Those finding no significant difference[70 79 80 83 84 131 132 135 137 138 153 154] had small sample sizes and only three used a fatigue scale.

Physical factors

The key physical factors associated with fatigue were dyspnoea, pulmonary functions, exercise capacity, comorbidities and ICU admission. An association between breathlessness and fatigue was found in three studies[79 84 85] and those with fatigue had a higher prevalence of breathlessness in four other studies.[82 83 129 155] At 3–6 months post infection, two did not find a relationship,[80 96] suggestive of improvements over time. Staudt et al (2021) found that 'respiratory symptoms' on the St George's Respiratory Questionnaire (SGRQ) were related to fatigue in multivariate analyses at 10 months post infection (OR=1.06,

Table 2 Variables associated with fatigue

Factor	Cross-sectional bivariate	Multivariate	Prospective cohort bivariate	Multivariate
PTSD↑	+ +		+ +	
Anxiety symptoms↑	+ 0 +	+	+	0
Depression↑	+ + + + + +	+ +	+ (0^6 $+^{12}$)	+ 0
Psychiatric morbidity↑			+	
Physical comorbidities	0 0 0	+ +	0 0	+ + + + + + +
Psychological distress			0	
Somatisation			+	0
Pulmonary functions	+ 0 0	0		0
Pneumonia (CXR)		+		
Disease severity↑	+ 0 -+0 0 0 0	+	+ 0 + 0 0 0 + 0 0 0 0 + ++0 0	0 0
Age↑	0–0 + - 0 0 -	-+0 0 0 + 0 0	0 0+0 0 0 0–0	+ 0 − + 0 +
ICU admission	0 0 + + ++0	0 0 +	+ 0 + +	
Female gender	+ + - 0 ++0 + + ++0 + + ++0 + + + +	+ + ++0	++0 + 0 ++0 + 0 + ++0	+ +++0 0 +
Ethnicity	0 0	0		
Marital status			0	
Rural/urban habitat			0	
Occupation type			0	
BMI/obesity/weight↑	0 ++0	0 0+0	0 0 0	0
Returned to work	+	+	0	
Employed				+
Retired				−
Exercise capacity <	+ + - -		0	0 0
Intubated/IMV	+		- ($-^3$ $+^6$) 0	+
Serum troponin-1			+	
Nucleic acid test (>14 days, 46–69 years old)	+	+		
Reduction of serum NfL levels			0	
Blood (eg, lymphocytes10^9/L, IgG)	0 + -	+	0	0
SpO$_2$				0 0
Gut microbiota	+			
% predicted VO$_2$			0	
Mean consecutive difference in extensor digitorum communis	+			
Alcohol consumption	0	0		
Smoking history	0 0 0	0 0		0 0
Length of stay >	0+0 0	+	0 +	
Hospital readmission				+
Education↑	0	0		
Physical health↓	0 +			+
Pain	+		+	
Post functional status/daily functioning↓	+ + + +			
Frailty↑			+	
Resilience↓	−			
Sleep (quality and quantity)	+ + +		+ 0	

Continued

Table 2 Continued

Factor	Cross-sectional bivariate	Multivariate	Prospective cohort bivariate	Multivariate
Steroid treatment	0 0			
Days since onset >	0	+		
Cognitive problems↑	+ + +		+	
Breathlessness/dyspnoea/hyperventilation↑	+ 0 +	+ 0	+ +	+ +
Post-COVID-19 functioning↓			+	+

BMI, body mass index; CXR, X-ray of the chest; ICU, intensive care unit; IgG, immunoglobulin G; NfL, serum neurofilament light chain; PTSD, post-traumatic stress disorder; SpO2, oxygen saturation; VO2, maximal oxygen consumption.

p=0.05). However, only two used a dyspnoea scale or a fatigue scale. All had small sample sizes, therefore potentially underpowered. Pulmonary functions were reported in five studies. Forced expiratory volume in one second (FEV_1) related to higher vitality in 1 (r=0.0.23, p<0.05),[78] but non-significant in the others.[79 80 155] These studies assessed survivors≥3 months, suggesting results are indicative of functional improvements overtime. Exercise capacity was generally poor in survivors[156] and seven studies examined its relationship with fatigue, with mixed results. Better exercise performance was associated with vitality (r=0.526, p<0.001),[78] but not with 4 m gait speed test[85] or 6MWT.[79] Two others found improved fatigue following a physical rehabilitation programme.[97 157] At 3 months post infection, fatigue was cited as the reason for halting a cardiopulmonary performance test or limiting exercise in three studies.[158–160] Myopathy was associated with fatigue in another small study of 20 people[161] suggestive of poor conditioning contributing to limited capacity. Generally, fatigue had an inverse relationship with exercise capacity in the early months. Where the relationship remained beyond 3 months,[78] patients were overweight/obese, which possibly affected performance. Also, all studies had small sample sizes limiting generalisability.

Physical comorbidities such as hypertension, asthma and diabetes were related to fatigue in nine studies.[52 63 68 126 128 136 146 148 162] Four found no relationship.[132 133 137 147] A large study of 4755 participants found hypertension increased the likelihood (OR=1.27, p=0.05) of persistent fatigue>6 months.[148] Yomogida et al[68] reported that having at least one comorbidity increased the risk for fatigue (OR=4.39, p<0.001). Moreover, worse physical health was related to fatigue (OR=10.48)[65 163 164] implying general poorer functioning among survivors.[165]

For those admitted to ICU, some experienced high fatigue (eight studies),[83 129 131] and lower vitality,[166 167] or had an increased likelihood for fatigue (OR=4.63).[52 128 168] Four studies found no association between ICU admission and worse fatigue or vitality.[42 169–171] Patients who received mechanical ventilation had lower vitality (M=50, 95% CI: 44 to 57) than a sex-matched and age-matched group (M=68, 95% CI: 67 to 69).[172] Similarly, more intubated patients had fatigue (38.1%) than non-intubated (29.9%).[173] One study found the proportion of fatigued participants was higher in the ward group (74%) compared with ICU (33%).[143] Disease severity also had an inconsistent impact on fatigue, with most studies finding no association with severe acute disease or fatigue prevalence in severity categories.[80 86 93 130 136 137 153 174–180] Six studies found a significant association with critical illness or a significantly higher proportion of fatigued in severe illness.[123 135 145 181–183] Two studies found a relationship between severity of acute illness and vitality,[184 185] although both had small samples and were single-centre designs. Interestingly, moderately severe COVID-19 related to fatigue (OR=2.1) in one study.[186] Even after a longer hospital stay, the relationship with fatigue was inconsistent with two finding significance,[52 124] while four did not.[69 98 137 149] Taken together, these results indicate an uncertain contribution of critical illness to fatigue, although the non-significant results chiefly occurred>6 months. However, the classification of disease severity varied between studies and countries making comparisons difficult.

Psychological factors

A relationship with anxiety was found up to 6 months post infection in three studies.[52 83 149] The fatigued had higher anxiety (56.3%) compared with non-fatigued (24.6%, p<0.001).[83 149] In contrast, no significant interaction between anxiety and fatigue at 1 month related to later fatigue.[187] Similar results were found for depression. Previous depression was associated with lower vitality (−12.05, p=0.005) in one study[96] and a higher proportion of fatigued had depressive symptoms in four other studies (p=0.004).[83 90 155 188] Other studies found consistently moderate positive correlations (r=0.470).[98 171 189] or increased fatigue scores (b=0.89, p=0.05) in those with depressive symptoms.[52] The relationship continued up until 12 months.[79 98] Four studies found that those with PTSD symptoms were fatigued[90 129] and PTSD was associated with fatigue at 6 and 12 months after infection.[98] Barizien et al[132] found higher scores on the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in those with fatigue (M=31, IQR=18) compared with those without fatigue (M=18, IQR=19, p<0.001). Generalisability of these results, however, is likely limited

due to modest sample sizes and single-centre designs. In addition, only three studies used a valid fatigue scale.

DISCUSSION

This review investigated the prevalence of persistent fatigue in survivors who had a confirmed diagnosis of SARS-CoV-2, using a mean of >30 days post infection. We found a considerable proportion of patients continued to experience fatigue up to 12 months after their initial illness, which was associated with some non-modifiable factors including female gender, age and modifiable factors such as anxiety, depression and post-traumatic stress. Our findings support other research indicating that fatigue is an important symptom in persistent postacute sequelae.[14 112 150 190–196] Rates of fatigue may depend on when it was measured and, in this respect, we found overall rates of fatigue decreased by 6% per month. Fatigue did not differ by hospitalisation status, indicating that the contribution of severe disease was not related to fatigue recovery for most people. This is consistent with previous reviews, which did not find support for the effects of critical illness on fatigue outcomes.[117 197] Respiratory impairments, a key clinical indicator, were associated with worse vitality post recovery (r=0.290, p=0.026),[78] although at 10 months, FEV_1 was not associated[79] implying that, as lung function improved, fatigue diminished. Indeed, rehabilitation aimed at improving functioning by incorporating aerobic exercises, improved vitality scores.[97 167 198] Some survivors, however, continued to experience dyspnoea, which was associated with their fatigue,[83–85] despite normal pulmonary tests.[80 159] Similarly, reduced exercise capacity, as a result of critical illness, is thought to contribute to reduced HRQoL and fatigue outcomes in recovered patients.[199] However, our review did not find a consistent relationship between exercise performance and worse fatigue in those who had more severe disease. It is possible that these limitations are related to diminished muscle function[199] and deconditioning. Rehabilitation programmes have led to improved vitality[157 198] and lower fatigue.[97 157] A 9-week telerehabilitation study of 115 participants, incorporating 2/3 aerobic exercises per week to improve physical capacity, reported significantly increased vitality scores from pre=40.7(SD=21.7) to post=58.5(SD=21.2), p=0.001.[167] While deconditioning could explain fatigue, persistent fatigue may be related to other variables including psychological factors.

Depression and anxiety were found to be correlated with fatigue in our review.[52 171] Moreover, these relationships were found some distance from the initial infection.[98 155] In a prospective study of 402 participants using a fatigue scale, Mazza et al found that both anxiety (r=0.48) and PTSD (r=0.52) were moderately correlated with fatigue at 12 months, post illness. These findings accord with critical illness studies[200] and systematic reviews suggesting that symptoms of depression, anxiety, PTSD and fatigue persist long after discharge.[197] For COVID-19, we cannot be certain of the longevity of psychological factors or their relationship to fatigue because the body of evidence is too small, but current literature indicates the relationship remains up to 6 months.[83 132] This fits with previous COVID-19 research indicating those with chronic fatigue were more likely to have psychiatric morbidity 4 years following SARS infection.[201] Similarly, those with psychiatric illness reported higher fatigue than those without (p<0.05) in survivors of SARS.[202]

Theoretical implications

The associations of fatigue persistence were multidimensional. Factors such as dyspnoea and comorbidities (eg, hypertension) were likely risk factors for fatigue in the shorter term, whereas psychological factors appeared more likely to be associated with fatigue longer term. The psychological risk factors could have been related to adverse effects of the pandemic as well as infection.[203 204] Taken together, these factors, alongside other mechanisms such as skeletal muscle deficits,[205] could lead to poorer global functioning and lower engagement in activities or exercise. Lower scores on objective walking tests and reduced physical functioning were associated with fatigue in some studies. We have summarised diagrammatically the factors associated with post-COVID-19 fatigue (see figure 3).

Practical implications

Our review suggests post-COVID-19 fatigue is complex, affecting multiple domains of physical and psychological well-being. While there were small improvements in fatigue over time, our review indicates that fatigue remains a significant problem for patients beyond their anticipated recovery time.[206] Pulmonary rehabilitation programmes have shown promise.[97 167 198] Our results also suggest that psychological interventions may benefit some survivors. Given fatigue is one of a number of post-COVID-19 symptoms,[207–210] an integrated management approach has been suggested.[211] Care pathways should identify those most at risk for long-term symptoms such as women and older people with comorbidities.

Future directions

Few studies have examined correlates between fatigue, physical and pulmonary functioning, psychological and social functioning in hospitalised and outpatients. Some research focuses on symptom 'clusters' or 'post-COVID-19 syndrome'[212–215] limiting understanding of fatigue processes specifically. Future studies should interrogate risk factors further to help inform the development of clinical interventions to address persistent fatigue. Furthermore, fatigue is the principal symptom for postillness patients, but there is little research into what mechanisms may ameliorate distress resulting from infection, and thus protect against long symptoms. Severity of the illness, for instance, was not conclusive in our study and nor was length of hospital stay, pointing to the importance of individual differences.

Figure 3 Diagram of post-COVID-19 fatigue findings. ICU, intensive care unit.

Limitations

The generalisability of our results should be applied with caution due to a number of limitations. First, we found considerable, unexplained between-study heterogeneity. Measurement error was not found to explain the inconsistency. However, diverse tools were used to measure fatigue in different populations. Non-validated questionnaires were unlikely to capture fatigue dimensions accurately given most only had 1–2 fatigue-related items. Moreover, scoring and cut-offs were under-reported, contributing to variability. Included studies could not adequately exclude 'pandemic-related fatigue' in their selections or definitions. Therefore, we recognise that our results could not completely exclude such fatigue and its potential influence on participants in the included studies. Some studies used particular populations, including older age or only those admitted to ICU, meaning they were not representative. Furthermore, our sample comprised primarily of hospitalised patients with potentially more severe disease. This was complicated by different admission and discharge protocols across countries, with some admitting all confirmed patients regardless of disease severity. This could explain why there was no difference between hospitalised and non-hospitalised survivors. We also encountered missing data, which reduced the reliability of our results. Moreover, Egger's tests suggested all but one analyses were asymmetric representing a high likelihood of publication bias. Small study effects were likely to affect precision. Larger studies, with more precise CIs, are likely

to be a more reliable indicator of fatigue proportions. Moreover, sample bias probably occurred due to recruitment from single-centre post-COVID-19 clinics[216–218] for persistent symptoms and therefore could be expected to have higher fatigue than controls or population norms. Different admission and discharge protocols and lung function reference ranges vary between countries.[219] Our results, therefore, should be viewed with this in mind. Methodologically, our study had only one reviewer for screening and data extraction, and we did not contact authors for missing data meaning our study was at higher risk for excluding relevant data. Other limitations include the inclusion of non-peer reviewed articles and those limited to English. For the meta-analysis, given the multiple assessment times, we incorporated one median follow-up time obtained from each study, which may not denote actual fatigue prevalence. Despite these limitations, we incorporated a substantial sample size likely to be a reasonable estimate of fatigue in this population.

CONCLUSION

This large review provides a broad illustration of fatigue outcomes and complements the body of information for persistent symptoms in those recovering from COVID-19. We report that fatigue decreases over time, but recovery pathways are potentially impeded by a number of risk factors, independent of disease severity or hospitalisation. Our study indicates the

need for long-term clinical and psychological rehabilitation support for survivors of COVID-19.

ORCID iDs
Kim Poole-Wright http://orcid.org/0000-0003-4842-901X
Ismail Guennouni http://orcid.org/0000-0002-1096-4714
Rachael A Evans http://orcid.org/0000-0002-1667-868X
Fiona Gaughran http://orcid.org/0000-0001-7414-5569
Trudie Chalder http://orcid.org/0000-0003-0775-1045

REFERENCES

1. Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue. *Journal of Psychosomatic Research* 2004;56:157–70.
2. Grant MC, Geoghegan L, Arbyn M, *et al*. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-cov-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. *PLoS One* 2020;15:e0234765.
3. Lemhöfer C, Sturm C, Loudovici-Krug D, *et al*. The impact of post-COVID-syndrome on functioning – results from a community survey in patients after mild and moderate SARS-cov-2-infections in Germany. *J Occup Med Toxicol* 2021;16:1–9.
4. Leth S, Gunst JD, Mathiasen V, *et al*. Persistent symptoms in patients recovering from COVID-19 in Denmark. *Open Forum Infect Dis* 2021;8:ofab042.
5. Liang L, Yang B, Jiang N, *et al*. Three-Month follow-up study of survivors of coronavirus disease 2019 after discharge. *J Korean Med Sci* 2020;35:e418.
6. Miyazato Y, Morioka S, Tsuzuki S, *et al*. Prolonged and late-onset symptoms of coronavirus disease 2019. *Open Forum Infect Dis* 2020;7:ofaa507.
7. Ortelli P, Ferrazzoli D, Sebastianelli L, *et al*. Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: insights into a challenging symptom. *J Neurol Sci* 2021;420:117271.
8. Rosales-Castillo A, García de los Ríos C, Mediavilla García JD. Persistent symptoms after acute COVID-19 infection: importance of follow-up. *Medicina Clínica (English Edition)* 2021;156:35–6.
9. Shoucri SM, Purpura L, DeLaurentis C, *et al*. Characterising the long-term clinical outcomes of 1190 hospitalised patients with COVID-19 in new york city: a retrospective case series. *BMJ Open* 2021;11:e049488.
10. Søraas A, Kalleberg KT, Dahl JA, *et al*. Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study. *PLoS One* 2021;16:e0256142.
11. Sultana S, Islam MT, Salwa M, *et al*. Duration and risk factors of post-COVID symptoms following recovery among the medical doctors in Bangladesh. *Cureus* 2021;13:e15351.
12. Zhou Y, Zhang J, Zhang D, *et al*. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. *J Microbiol* 2021;59:941–8.
13. Badenoch JB, Rengasamy ER, Watson C, *et al*. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. *Brain Communications* 2022;4.
14. Hoshijima H, Mihara T, Seki H, *et al*. Incidence of long-term post-acute sequelae of SARS-cov-2 infection related to pain and other symptoms: A living systematic review and meta-analysis. *Infectious Diseases (except HIV/AIDS)* [Preprint].
15. Cares-Marambio K, Montenegro-Jiménez Y, Torres-Castro R, *et al*. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *Chron Respir Dis* 2021;18:14799731211002240.
16. Malik P, Patel K, Pinto C, *et al*. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (hrqol)-A systematic review and meta-analysis. *J Med Virol* 2022;94:253–62.
17. Mak IWC, Chu CM, Pan PC, *et al*. Long-Term psychiatric morbidities among SARS survivors. *Gen Hosp Psychiatry* 2009;31:318–26.
18. Lee SH, Shin H-S, Park HY, *et al*. Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in middle East respiratory syndrome survivors. *Psychiatry Investig* 2019;16:59–64.
19. Arnold DT, Hamilton FW, Milne A, *et al*. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. *Thorax* 2021;76:399–401.
20. Becker C, Beck K, Zumbrunn S, *et al*. Long covid 1 year after hospitalisation for covid-19: a prospective bicentric cohort study. *Swiss Med Wkly* 2021;151.
21. Bozzetti S, Ferrari S, Zanzoni S, *et al*. Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae? *Immunol Res* 2021;69:553–7.
22. Catalán IP, Martí CR, Sota DP de la, *et al*. Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission. *J Med Virol* 2022;94:205–10.
23. Eloy P, Tardivon C, Martin-Blondel G, *et al*. Severity of self-reported symptoms and psychological burden 6-months after hospital admission for covid-19: a prospective cohort study. *Int J Infect Dis* 2021;112:247–53.
24. Evans RA, McAuley H, Harrison EM, *et al*. Physical, cognitive, and mental health impacts of covid-19 after hospitalisation (phosp-covid): a uk multicentre, prospective cohort study. *Lancet Respir Med* 2021;9:1275–87.
25. Fatima G, Bhatt D, Idrees J, *et al*. Elucidating post-COVID-19 manifestations in india. *Infectious Diseases (except HIV/AIDS)* [Preprint].

26 Fortini A, Torrigiani A, Sbaragli S, *et al*. COVID-19: persistence of symptoms and lung alterations after 3-6 months from hospital discharge. *Infection* 2021;49:1007–15.

27 Ganesh R, Ghosh AK, Nyman MA, *et al*. PROMIS scales for assessment of the impact of post-COVID syndrome: A cross sectional study. *Infectious Diseases (except HIV/AIDS)* [Preprint].

28 García-Abellán J, Padilla S, Fernández-González M, *et al*. Antibody response to SARS-cov-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. *J Clin Immunol* 2021;41:1490–501.

29 Kayaaslan B, Eser F, Kalem AK, *et al*. Post-COVID syndrome: a single-center questionnaire study on 1007 participants recovered from COVID-19. *J Med Virol* 2021;93:6566–74.

30 Khalaf M, Bazeed SE, Abdel-Gawad M, *et al*. Prevalence and predictors of persistent symptoms after clearance of SARS-cov-2 infection: a report from Egypt. *SSRN Journal* 2020.

31 Mahmud R, Rahman MdM, Rassel MA, *et al*. Post-COVID-19 syndrome among symptomatic COVID-19 patients: a prospective cohort study in a tertiary care center of Bangladesh. *PLoS ONE* 2021;16:e0249644.

32 Moreno-Pérez O, Merino E, Leon-Ramirez J-M, *et al*. Post-Acute COVID-19 syndrome. incidence and risk factors: a Mediterranean cohort study. *Journal of Infection* 2021;82:378–83.

33 Poyraz BÇ, Poyraz CA, Olgun Y, *et al*. Psychiatric morbidity and protracted symptoms after COVID-19. *Psychiatry Res* 2021;295:113604.

34 Righi E, Mirandola M, Mazzaferri F, *et al*. Long-Term patient-centred follow-up in a prospective cohort of patients with COVID-19. *Infect Dis Ther* 2021;10:1579–90.

35 Scherlinger M, Felten R, Gallais F, *et al*. Refining "long-COVID" by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-cov-2 infection. *Infect Dis Ther* 2021;10:1747–63.

36 Seeßle J, Waterboer T, Hippchen T, *et al*. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. *Clin Infect Dis* 2022;74:1191–8.

37 Steinbeis F, Thibeault C, Doellinger F, *et al*. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-cov-2: an observational longitudinal study over 12 months. *Respir Med* 2022;191:106709.

38 Tleyjeh IM, Saddik B, AlSwaidan N, *et al*. Prevalence and predictors of post-acute COVID-19 syndrome (PACS) after hospital discharge: a cohort study with 4 months median follow-up. *PLoS ONE* 2021;16:e0260568.

39 van Veenendaal N, van der Meulen IC, Onrust M, *et al*. Six-Month outcomes in COVID-19 ICU patients and their family members: a prospective cohort study. *Healthcare* 2021;9:865.

40 Wu Q, Zhong L, Li H, *et al*. A follow-up study of lung function and chest computed tomography at 6 months after discharge in patients with coronavirus disease 2019. *Can Respir J* 2021;2021:6692409.

41 Zayet S, Zahra H, Royer P-Y, *et al*. Post-COVID-19 syndrome: nine months after SARS-cov-2 infection in a cohort of 354 patients: data from the first wave of COVID-19 in Nord franche-comté Hospital, France. *Microorganisms* 2021;9:1719.

42 Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, *et al*. Fatigue and dyspnoea as main persistent post-COVID-19 symptoms in previously hospitalized patients: related functional limitations and disability. *Respiration* 2022;101:132–41.

43 Gamberini L, Mazzoli CA, Prediletto I, *et al*. Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after icu discharge in invasively ventilated covid-19 patients, a prospective follow-up study. *Respir Med* 2021;189:106665.

44 Boari GEM, Bonetti S, Braglia-Orlandini F, *et al*. Short-Term consequences of SARS-cov-2-related pneumonia: a follow up study. *High Blood Press Cardiovasc Prev* 2021;28:373–81.

45 Creamer A, Alaee S, Iftikhar H, *et al*. P175 Clinico-radiological recovery following severe covid-19 pneumonia. British Thoracic Society Winter Meeting, Wednesday 17 to Friday 19 February 2021, Programme and Abstracts; February 2021

46 Horwitz LI, Garry K, Prete AM, *et al*. Six-Month outcomes in patients hospitalized with severe COVID-19. *J GEN INTERN MED* 2021;36:3772–7.

47 Naik S, Haldar SN, Soneja M, *et al*. Post COVID-19 sequelae: a prospective observational study from northern India. *DD&T* 2021;15:254–60.

48 Frontera JA, Yang D, Lewis A, *et al*. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. *Journal of the Neurological Sciences* 2021;426:117486.

49 Gupta A, Garg I, Iqbal A, *et al*. Long-Term X-ray findings in patients with coronavirus disease-2019. *Cureus* 2021.

50 Kozak R, Armstrong SM, Salvant E, *et al*. Recognition of long-COVID-19 patients in a Canadian tertiary hospital setting: a retrospective analysis of their clinical and laboratory characteristics. *Pathogens* 2021;10:1246.

51 Liu T, Wu D, Yan W, *et al*. Twelve-month systemic consequences of coronavirus disease 2019 (COVID-19) in patients discharged from Hospital: a prospective cohort study in Wuhan, China. *Clinical Infectious Diseases* 2022;74:1953–65.

52 Qin ES, Gold LS, Hough CL, *et al*. Patient-reported functional outcomes 30 days after hospitalization for COVID-19. *PM R* 2022;14:173–82.

53 Bell ML, Catalfamo CJ, Farland LV, *et al*. n.d. Post-Acute sequelae of COVID-19 in a non-hospitalized cohort: results from the Arizona covhort. *PLoS ONE*;16:e0254347.

54 Carvalho-Schneider C, Laurent E, Lemaignen A, *et al*. Follow-up of adults with noncritical COVID-19 two months after symptom onset. *Clin Microbiol Infect* 2021;27:258–63.

55 Graham EL, Clark JR, Orban ZS, *et al*. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized covid-19 "long haulers." *Ann Clin Transl Neurol* 2021;8:1073–85.

56 Savarraj JP, Burkett AB, Hinds SN, *et al*. Three-month outcomes in hospitalized COVID-19 patients. *Neurology* [Preprint].

57 Senjam SS, Balhara YPS, Kumar P, *et al*. Assessment of post COVID-19 health problems and its determinants in north india: A descriptive cross section study. *Public and Global Health* [Preprint].

58 Boscolo-Rizzo P, Guida F, Polesel J, *et al*. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). *Int Forum Allergy Rhinol* 2021;11:1685–8.

59 Bliddal S, Banasik K, Pedersen OB, *et al*. Acute and persistent symptoms in non-hospitalized pcr-confirmed covid-19 patients. *Sci Rep* 2021;11:13153.

60 Logue JK, Franko NM, McCulloch DJ, *et al*. Sequelae in adults at 6 months after COVID-19 infection. *JAMA Netw Open* 2021;4:e210830.

61 Castro VM, Rosand J, Giacino JT, *et al*. Case-control study of neuropsychiatric symptoms following covid-19 hospitalization in 2 academic health systems. *MedRxiv* 2021:2021.07.09.21252353.

62 Heightman M, Prashar J, Hillman TE, *et al*. Post-COVID assessment in a specialist clinical service: a 12-month, single-centre analysis of symptoms and healthcare needs in 1325 individuals. *Epidemiology* [Preprint].

63 Amin-Chowdhury Z, Harris RJ, Aiano F, *et al*. Characterising post-COVID syndrome more than 6 months after acute infection in adults; prospective longitudinal cohort study, england. *Infectious Diseases (except HIV/AIDS)* [Preprint].

64 Bai F, Tomasoni D, Falcinella C, *et al*. Female gender is associated with long covid syndrome: a prospective cohort study. *Clin Microbiol Infect* 2022;28:611.

65 Hellemons ME, Huijts S, Bek LM, *et al*. Persistent health problems beyond pulmonary recovery up to 6 months after hospitalization for covid-19: a longitudinal study of respiratory, physical, and psychological outcomes. *Ann Am Thorac Soc* 2022;19:551–61.

66 Lombardo MDM, Foppiani A, Peretti GM, *et al*. Long-Term coronavirus disease 2019 complications in inpatients and outpatients: a one-year follow-up cohort study. *Open Forum Infect Dis* 2021;8:ofab384.

67 Daugherty SE, Guo Y, Heath K, *et al*. Risk of clinical sequelae after the acute phase of SARS-cov-2 infection: retrospective cohort study. *BMJ* 2021;373:n1098.

68 Yomogida K, Zhu S, Rubino F, *et al*. Post-acute sequelae of SARS-cov-2 infection among adults aged ≥18 years - long beach, california, april 1-december 10, 2020. *MMWR Morb Mortal Wkly Rep* 2021;70:1274–7.

69 Karaarslan F, Demircioğlu Güneri F, Kardeş S. Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews. *Rheumatol Int* 2021;41:1263–71.

70 Hossain MA, Hossain KMA, Saunders K, *et al*. Prevalence of long COVID symptoms in Bangladesh: a prospective inception cohort study of COVID-19 survivors. *BMJ Glob Health* 2021;6:e006838.

71 Cao J, Zheng X, Wei W, *et al*. Three-month outcomes of recovered COVID-19 patients: prospective observational study. *Ther Adv Respir Dis* 2021;15:17534666211009410.

72 Aranda J, Oriol I, Martín M, *et al*. Long-Term impact of COVID-19 associated acute respiratory distress syndrome. *Journal of Infection* 2021;83:581–8.

73 Szekely Y, Lichter Y, Sadon S, *et al*. Cardiorespiratory abnormalities in patients recovering from coronavirus disease 2019. *Journal of the American Society of Echocardiography* 2021;34:1273–1284.

74 Wang SY, Adejumo P, See C, *et al*. Characteristics of patients referred to a cardiovascular disease clinic for post-acute sequelae of SARS-cov-2 infection. *Cardiovascular Medicine* [Preprint].

75 Donaghy M, McKeegan D, Walker J, *et al*. Follow up for COVID-19 in belfast city hospital. *Ulster Med J* 2021;90:157–61.

76 Chudzik M, Burzyńska M, Kapusta J. n.d. Use of 1-MNA to improve exercise tolerance and fatigue in patients after COVID-19. *Nutrients*;14:3004.

77 Chen Y, Liu C, Wang T, *et al*. Efficacy and safety of bufei huoxue capsules in the management of convalescent patients with COVID-19 infection: a multicentre, double-blind, and randomised controlled trial. *Journal of Ethnopharmacology* 2022;284:114830.

78 Bardakci MI, Ozturk EN, Ozkarafakili MA, *et al*. Evaluation of long-term radiological findings, pulmonary functions, and health-related quality of life in survivors of severe COVID-19. *J Med Virol* 2021;93:5574–81.

79 Staudt A, Jörres RA, Hinterberger T, *et al*. Associations of post-acute COVID syndrome with physiological and clinical measures 10 months after hospitalization in patients of the first wave. *Eur J Intern Med* 2022;95:50–60.

80 Froidure A, Mahsouli A, Liistro G, *et al*. Integrative respiratory follow-up of severe covid-19 reveals common functional and lung imaging sequelae. *Respir Med* 2021;181:106383.

81 Smet J, Stylemans D, Hanon S, *et al*. Clinical status and lung function 10 weeks after severe SARS-cov-2 infection. *Respiratory Medicine* 2021;176:106276.

82 Aparisi Á, Ybarra-Falcón C, García-Gómez M, *et al*. Exercise ventilatory inefficiency in post-COVID-19 syndrome: insights from a prospective evaluation. *J Clin Med* 2021;10:2591.

83 González-Hermosillo JA, Martínez-López JP, Carrillo-Lampón SA, *et al*. Post-acute COVID-19 symptoms, A potential link with myalgic encephalomyelitis/chronic fatigue syndrome: A 6-month survey in A mexican cohort. *Brain Sci* 2021;11:760.

84 Shendy W, Elsherif AA, Ezzat MM, *et al*. Prevalence of fatigue in patients post covid-19. *European Journal of Molecular and Clinical Medicine* 2021;8:1330–40.

85 D'Cruz RF, Waller MD, Perrin F, *et al*. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. *ERJ Open Res* 2021;7:00655–2020.

86 Andrade Barreto AP, Duarte LC, Cerqueira-Silva T, *et al*. Post-acute COVID syndrome, the aftermath of mild to severe COVID-19 in brazilian patients. *Infectious Diseases (except HIV/AIDS)* [Preprint] 2021.

87 Taboada M, Moreno E, Cariñena A, *et al*. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. *Br J Anaesth* 2021;126:e110–3.

88 Taylor RR, Trivedi B, Patel N, *et al*. Post-COVID symptoms reported at asynchronous virtual review and stratified follow-up after COVID-19 pneumonia. *Clin Med (Lond)* 2021;21:e384–91.

89 Daher A, Balfanz P, Cornelissen C, *et al*. Follow up of patients with severe coronavirus disease 2019 (COVID-19): pulmonary and extrapulmonary disease sequelae. *Respir Med* 2020;174:106197.

90 Liyanage-Don NA, Cornelius T, Sanchez JE, *et al*. Psychological distress, persistent physical symptoms, and perceived recovery after COVID-19 illness. *J Gen Intern Med* 2021;36:2525–7.

91 Rogers JP, Chesney E, Oliver D, *et al*. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *The Lancet Psychiatry* 2020;7:611–27.

92 Suárez-Robles M, Iguaran-Bermúdez MDR, García-Klepizg JL, *et al*. Ninety days post-hospitalization evaluation of residual covid-19 symptoms through a phone call check list. *Pan Afr Med J* 2020;37:289.

93 Voruz P, Allali G, Benzakour L, *et al*. n.d. Long COVID neuropsychological deficits after severe, moderate, or mild infection. *CTN*;6:9.

94 Weerahandi H, Hochman KA, Simon E, *et al*. Post-Discharge health status and symptoms in patients with severe COVID-19. *J GEN INTERN MED* 2021;36:738–45.

95 Domingo FR, Waddell LA, Cheung AM, *et al*. Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review. *Epidemiology* [Preprint].

96 Stavem K, Ghanima W, Olsen MK, *et al*. Prevalence and determinants of fatigue after covid-19 in non-hospitalized subjects: a population-based study. *IJERPH* 2021;18:2030.

97 Daynes E, Gerlis C, Chaplin E, *et al*. Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition - A cohort study. *Chron Respir Dis* 2021;18:14799731211015692.

98 Mazza MG, Palladini M, De Lorenzo R, *et al*. One-Year mental health outcomes in a cohort of COVID-19 survivors. *Journal of Psychiatric Research* 2022;145:118–24.

99 Mirfazeli FS, Sarabi-Jamab A, kordi A, *et al*. Acute phase clinical manifestation of COVID-19 is linked to long-COVID symptoms; A 9-month follow-up study. *Psychiatry and Clinical Psychology* [Preprint].

100 Page MJ, Moher D, Bossuyt PM, *et al*. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ* 2021;372:n160:160.:.

101 Ouzzani M, Hammady H, Fedorowicz Z, *et al*. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* 2016;5:210:210.:.

102 Aromataris E, Munn Z. Chapter 7: systematic reviews of etiology and risk. In: Aromataris E, Munn Z, eds. *JBI reviewer's manual*.

103 Sera F, Armstrong B, Blangiardo M, *et al*. An extended mixed-effects framework for meta-analysis. *Stat Med* 2019;38:5429–44.

104 RStudio. *RStudio: integrated development environment for R*. RStudio, 2020.

105 Higgins JPT, Thompson SG, Deeks JJ, *et al*. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.

106 Aiyegbusi OL, Hughes SE, Turner G, *et al*. Symptoms, complications and management of long COVID: a review. *J R Soc Med* 2021;114:428–42.

107 Amdal CD, Pe M, Falk RS, *et al*. Health-Related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. *Qual Life Res* 2021;30:3367–81.

108 Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, *et al*. Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review. *Int J Clin Pract* 2021;75:e14357.

109 Cha C, Baek G. Symptoms and management of long COVID: a scoping review. *Journal of Clinical Nursing* 2021.

110 Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, *et al*. Prevalence of post-covid-19 symptoms in hospitalized and non-hospitalized covid-19 survivors: a systematic review and meta-analysis. *Eur J Intern Med* 2021;92:55–70.

111 Garg M, Maralakunte M, Garg S, *et al*. The conundrum of "long-covid-19": a narrative review. *Int J Gen Med* 2021;14:2491–506.

112 Jennings G, Monaghan A, Xue F, *et al*. A systematic review of persistent symptoms and residual abnormal functioning following acute COVID-19: ongoing symptomatic phase vs. post-COVID-19 syndrome. *Epidemiology* [Preprint].

113 Korompoki E, Gavriatopoulou M, Hicklen RS, *et al*. Epidemiology and organ specific sequelae of post-acute covid19: a narrative review. *J Infect* 2021;83:1–16.

114 Long Q, Li J, Hu X, *et al*. n.d. Follow-ups on persistent symptoms and pulmonary function among post-acute COVID-19 patients: a systematic review and meta-analysis. *Front Med*;8.

115 Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. *JAMA Netw Open* 2021;4:e2111417.

116 Poudel AN, Zhu S, Cooper N, *et al*. Impact of covid-19 on health-related quality of life of patients: a structured review. *PLoS One* 2021;16:e0259164.

117 Rao S, Benzouak T, Gunpat S, *et al*. Fatigue symptoms associated with COVID-19 in convalescent or recovered COVID-19 patients; a systematic review and meta-analysis. *Annals of Behavioral Medicine* 2022;56:219–34.

118 Sanchez-Ramirez DC, Normand K, Zhaoyun Y, *et al*. Long-term impact of COVID-19: A systematic review of the literature and meta-analysis. *Biomedicines* 2021;9:900.

119 Shanbehzadeh S, Tavahomi M, Zanjari N, *et al*. Physical and mental health complications post-COVID-19: scoping review. *J Psychosom Res* 2021;147:110525.

120 Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-A systemic review and comparison of clinical presentation and symptomatology. *Medicina (Kaunas)* 2021;57:418.

121 Chen C, Haupert SR, Zimmermann L, *et al*. Global prevalence of post-acute sequelae of COVID-19 (PASC) or long COVID: A meta-analysis and systematic review. *Epidemiology* [Preprint].

122 Matcham F, Ali S, Hotopf M, *et al*. Psychological correlates of fatigue in rheumatoid arthritis: a systematic review. *Clin Psychol Rev* 2015;39:16–29.

123 Zhang X, Wang F, Shen Y, *et al*. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. *JAMA Netw Open* 2021;4:e2127403.

124 Chen K-Y, Li T, Gong F-H, *et al*. Predictors of health-related quality of life and influencing factors for COVID-19 patients, a follow-up at one month. *Front Psychiatry* 2020;11:668.

125 Nehme M, Braillard O, Chappuis F, *et al*. Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting. *Ann Intern Med* 2021;174:1252–60.

126 Pauley E, Drake TM, Griffith DM, *et al*. n.d. Recovery from covid-19 critical illness: a secondary analysis of the ISARIC4C CCP-UK cohort study and the recover trial. *Journal of the Intensive Care Society*:175114372110522.

127 Henneghan AM, Lewis KA, Gill E, *et al*. Describing cognitive function and psychosocial outcomes of COVID-19 survivors: a cross-sectional analysis. *J Am Assoc Nurse Pract* 2022;34:499–508.

128 Menges D, Ballouz T, Anagnostopoulos A, *et al*. n.d. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. *PLoS ONE*;16:e0254523.

129 Halpin SJ, McIvor C, Whyatt G, *et al*. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. *J Med Virol* 2021;93:1013–22.

130 Shang YF, Liu T, Yu JN, *et al*. Half-year follow-up of patients recovering from severe COVID-19: analysis of symptoms and their risk factors. *J Intern Med* 2021;290:444–50.

131 Aul DR, Gates DJ, Draper DA, *et al*. Complications after discharge with covid-19 infection and risk factors associated with development of post-covid pulmonary fibrosis. *Respir Med* 2021;188:106602.

132 Barizien N, Le Guen M, Russel S, *et al*. Clinical characterization of dysautonomia in long covid-19 patients. *Sci Rep* 2021;11:14042.

133 Desgranges F, Tadini E, Munting A, *et al*. Post-COVID-19 syndrome in outpatients: a cohort study. *Infectious Diseases (except HIV/AIDS)* [Preprint].

134 Molnar T, Varnai R, Schranz D, *et al*. Severe fatigue and memory impairment are associated with lower serum level of anti-SARS-cov-2 antibodies in patients with post-COVID symptoms. *JCM* 2021;10:4337.

135 Rauch B, Kern-Matschilles S, Haschka SJ, *et al*. COVID-19-related symptoms 6 months after the infection - update on a prospective cohort study in germany. *Infectious Diseases (except HIV/AIDS)* [Preprint].

136 Sigfrid L, Drake TM, Pauley E, *et al*. Long covid in adults discharged from UK hospitals after covid-19: a prospective, multicentre cohort study using the ISARIC who clinical characterisation protocol. *The Lancet Regional Health - Europe* 2021;8:100186.

137 Elkan M, Dvir A, Zaidenstein R, *et al*. Patient-reported outcome measures after hospitalization during the COVID-19 pandemic: A survey among COVID-19 and non-COVID-19 patients. *Int J Gen Med* 2021;14:4829–36.

138 Guo L, Lin J, Ying W, *et al*. Correlation study of short-term mental health in patients discharged after coronavirus disease 2019 (COVID-19) infection without comorbidities: A prospective study. *Neuropsychiatr Dis Treat* 2020;16:2661–7.

139 Aydin S, Unver E, Karavas E, *et al*. Computed tomography at every step: long coronavirus disease. *Respir Investig* 2021;59:622–7.

140 Lindahl A, Aro M, Reijula J, *et al*. Women report more symptoms and impaired quality of life: a survey of Finnish COVID-19 survivors. *Infectious Diseases* 2022;54:53–62.

141 Pérez-González A, Araújo-Ameijeiras A, Fernández-Villar A, *et al*. Long COVID in hospitalized and non-hospitalized patients in a large cohort in northwest spain, a prospective cohort study. *Infectious Diseases (except HIV/AIDS)* [Preprint].

142 Romero-Duarte Á, Rivera-Izquierdo M, Guerrero-Fernández de Alba I, *et al*. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. *BMC Med* 2021;19:129.

143 Sykes DL, Holdsworth L, Jawad N, *et al*. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? *Lung* 2021;199:113–9.

144 Boesl F, Audebert H, Endres M, *et al*. A neurological outpatient clinic for patients with post-covid-19 syndrome - A report on the clinical presentations of the first 100 patients. *Front Neurol* 2021;12:738405.

145 Iqbal A, Iqbal K, Arshad Ali S, *et al*. The COVID-19 sequelae: a cross-sectional evaluation of post-recovery symptoms and the need for rehabilitation of COVID-19 survivors. *Cureus* 2021;13.

146 Bek LM, Berentschot JC, Heijenbrok-Kal MH, *et al*. Symptoms persisting after hospitalisation for COVID-19: 12 months interim results of the co-flow study. *ERJ Open Res* 2022;8:00355-2022.

147 Kashif A, Chaudhry M, Fayyaz T, *et al*. Follow-up of COVID-19 recovered patients with mild disease. *Sci Rep* 2021;11:13414.

148 Munblit D, Bobkova P, Spiridonova E, *et al*. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19. *Clin Exp Allergy* 2021;51:1107–20.

149 Townsend L, Dyer AH, Jones K, *et al*. Persistent fatigue following SARS-cov-2 infection is common and independent of severity of initial infection. *PLoS One* 2020;15:e0240784.

150 Venturelli S, Benatti SV, Casati M, *et al*. Surviving COVID-19 in bergamo Province: a post-acute outpatient re-evaluation. *Epidemiol Infect* 2021;149.

151 Maamar M, Artime A, Pariente E, *et al*. POST-covid-19 syndrome, inflammatory markers and sex differences. *Infectious Diseases (except HIV/AIDS)* [Preprint].

152 Augustin M, Schommers P, Stecher M, *et al*. Post-covid syndrome in non-hospitalised patients with covid-19: a longitudinal prospective cohort study. *Lancet Reg Health Eur* 2021;6:100122.

153 P. S, Madhavan S, Pandurangan V. Prevalence, pattern and functional outcome of post COVID-19 syndrome in older adults. *Cureus* 2021.

154 Gebhard CE, Sütsch C, Bengs S, *et al*. Understanding the impact of sociocultural gender on post-acute sequelae of covid-19: a bayesian approach. *Infectious Diseases (except HIV/AIDS)* [Preprint].

155 Mantovani E, Mariotto S, Gabbiani D, *et al*. Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors? *J Neurovirol* 2021;27:631–7.

156 Latronico N, Peli E, Calza S, *et al*. Physical, cognitive and mental health outcomes in 1-year survivors of COVID-19-associated ARDS. *Thorax* 2022;77:300–3.

157 Ferraro F, Calafiore D, Dambruoso F, *et al*. COVID-19 related fatigue: which role for rehabilitation in post-COVID-19 patients? A case series. *J Med Virol* 2021;93:1896–9.

158 Clavario P, De Marzo V, Lotti R, *et al*. Assessment of functional capacity with cardiopulmonary exercise testing in non-severe COVID-19 patients at three months follow-up. *Cardiovascular Medicine* [Preprint] 2020.

159 Mancini DM, Brunjes DL, Lala A, *et al*. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post–coronavirus disease. *JACC: Heart Failure* 2021;9:927–37.

160 Raman B, Cassar MP, Tunnicliffe EM, *et al*. Medium-Term effects of SARS-cov-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. *EClinicalMedicine* 2021;31:100683.

161 Agergaard J, Leth S, Pedersen TH, *et al*. Myopathic changes in patients with long-term fatigue after covid-19. *Clin Neurophysiol* 2021;132:1974–81.

162 Chen X, Li Y, Shao T-R, *et al*. Some characteristics of clinical sequelae of COVID-19 survivors from Wuhan, China: a multi-center longitudinal study. *Influenza Other Respir Viruses* 2022;16:395–401.

163 O'Keefe JB, Minton HC, Morrow M, *et al*. Postacute sequelae of SARS-cov-2 infection and impact on quality of life 1-6 months after illness and association with initial symptom severity. *Open Forum Infect Dis* 2021;8:ofab352.

164 Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, *et al*. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. *PLoS One* 2020;15:e0243882.

165 Dini M, Poletti B, Tagini S, *et al*. Resilience, psychological well-being and daily functioning following hospitalization for respiratory distress due to SARS-cov-2 infection. *Healthcare (Basel)* 2021;9:1161.

166 Valent A, Dudoignon E, Ressaire Q, *et al*. Three-Month quality of life in survivors of ARDS due to COVID-19: a preliminary report from a French academic centre. *Anaesthesia Critical Care & Pain Medicine* 2020;39:740–1.

167 Dalbosco-Salas M, Torres-Castro R, Rojas Leyton A, *et al*. Effectiveness of a primary care telerehabilitation program for post-covid-19 patients: a feasibility study. *J Clin Med* 2021;10:4428.

168 Nune A, Durkowski V, Titman A, *et al*. Incidence and risk factors of long COVID in the UK: a single-centre observational study. *J R Coll Physicians Edinb* 2021;51:338–43.

169 Garrigues E, Janvier P, Kherabi Y, *et al*. Post-discharge persistent symptoms and health-related quality of life after hospitalization for covid-19. *J Infect* 2020;81:e4–6.

170 Yildirim S, Ediboglu O, Kirakli C, *et al*. Do covid-19 patients needing ICU admission have worse 6 months follow up outcomes when compared with hospitalized non-ICU patients? A prospective cohort study. *Intensive Care Med Exp* 2021;9.

171 Albu S, Zozaya NR, Murillo N, *et al*. What's going on following acute COVID-19? clinical characteristics of patients in an out-patient rehabilitation program. *NeuroRehabilitation* 2021;48:469–80.

172 Schandl A, Hedman A, Lyngå P, *et al*. Long-term consequences in critically ill COVID-19 patients: a prospective cohort study. *Acta Anaesthesiol Scand* 2021;65:1285–92.

173 The Writing Committee for the COMEBAC Study Group, Morin L, Savale L, *et al*. Four-Month clinical status of a cohort of patients after hospitalization for COVID-19. *JAMA* 2021;325:1525.

174 Sami R, Soltaninejad F, Amra B, *et al*. A one-year hospital-based prospective COVID-19 open-cohort in the eastern mediterranean region: the khorshid COVID cohort (KCC) study. *PLoS One* 2020;15:e0241537.

175 Anaya J-M, Rojas M, Salinas ML, *et al*. Post-covid syndrome. a case series and comprehensive review. *Infectious Diseases (except HIV/AIDS)* [Preprint].

176 Kanberg N, Simrén J, Edén A, *et al*. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. *EBioMedicine* 2021;70:103512.

177 Noviello D, Costantino A, Muscatello A, *et al*. Functional gastrointestinal and somatoform symptoms five months after SARS-cov-2 infection: a controlled cohort study. *Neurogastroenterol Motil* 2022;34:e14187.

178 Zhao Y, Yang C, An X, *et al*. Follow-up study on covid-19 survivors one year after discharge from hospital. *Int J Infect Dis* 2021;112:173–82.

179 Strumiliene E, Zeleckiene I, Bliudzius R, *et al*. Follow-up analysis of pulmonary function, exercise capacity, radiological changes, and quality of life two months after recovery from SARS-cov-2 pneumonia. *Medicina (Kaunas)* 2021;57:568.

180 Rass V, Ianosi B-A, Zamarian L, *et al*. Factors associated with impaired quality of life three months after being diagnosed with COVID-19. *Qual Life Res* 2022;31:1401–14.

181 Peghin M, Palese A, Venturini M, *et al*. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. *Clin Microbiol Infect* 2021;27:1507–13.

182 Fang X, Ming C, Cen Y, *et al*. Post-sequelae one year after hospital discharge among older COVID-19 patients: a multi-center prospective cohort study. *Journal of Infection* 2022;84:179–86.

183 Labarca G, Henríquez-Beltrán M, Lastra J, *et al*. Analysis of clinical symptoms, radiological changes and pulmonary function data 4 months after COVID-19. *Clin Respir J* 2021;15:992–1002.

184 van den Borst B, Peters JB, Brink M, *et al*. Comprehensive health assessment 3 months after recovery from acute coronavirus disease 2019 (COVID-19). *Clin Infect Dis* 2021;73:e1089–98.

185 van der Sar - van der Brugge S, Talman S, Boonman - de Winter L, *et al*. Pulmonary function and health-related quality of life after COVID-19 pneumonia. *Respiratory Medicine* 2021;176:106272.

186 Pilotto A, Cristillo V, Cotti Piccinelli S, *et al*. Long-Term neurological manifestations of COVID-19: prevalence and predictive factors. *Neurol Sci* 2021;42:4903–7.

187 Bottemanne H, Gouraud C, Hulot J-S, *et al*. Do anxiety and depression predict persistent physical symptoms after a severe COVID-19 episode? A prospective study. *Front Psychiatry* 2021;12:757685.

188 Tomasoni D, Bai F, Castoldi R, *et al*. Anxiety and depression symptoms after virological clearance of COVID-19: a cross-sectional study in Milan, Italy. *J Med Virol* 2021;93:1175–9.

189 Silva LS, Joao RB, Nogueira MH, *et al*. Functional and microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19. *Neurology* [Preprint].

190 Elanwar R, Hussein M, Magdy R, *et al*. Physical and mental fatigue in subjects recovered from covid-19 infection: a case-control study. *Neuropsychiatr Dis Treat* 2021;17:2063–71.

191 Danesh V, Arroliga AC, Bourgeois JA, *et al*. Post-acute sequelae of COVID-19 in adults referred to COVID recovery clinic services in an integrated health system in texas. *Proc (Bayl Univ Med Cent)* 2021;34:645–8.

192 Mandal S, Barnett J, Brill SE, *et al*. "Long-COVID": A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. *Thorax* 2021;76:396–8.

193 Moradian ST, Parandeh A, Khalili R, *et al*. Delayed symptoms in patients recovered from COVID-19. *Iran J Public Health* 2020;49:2120–7.

194 Tiwari B, Ghimire M, Bhatta G, *et al*. Persistent symptoms in non-critical COVID-19 patients at two months follow-up in A district hospital: A descriptive cross-sectional study. *JNMA J Nepal Med Assoc* 2021;59:550–3.

195 Tosato M, Carfì A, Martis I, *et al*. Prevalence and predictors of persistence of COVID-19 symptoms in older adults: A single-center study. *J Am Med Dir Assoc* 2021;22:1840–4.

196 Zulu JE, Banda D, Hines JZ, *et al*. Two-month follow-up of persons with SARS-cov-2 infection—zambia, september 2020. *Epidemiology* [Preprint] 2020.

197 Ahmed H, Patel K, Greenwood DC, *et al*. Long-Term clinical outcomes in survivors of severe acute respiratory syndrome and middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. *J Rehabil Med* 2020;52:jrm00063.

198 Liu K, Zhang W, Yang Y, *et al*. Respiratory rehabilitation in elderly patients with COVID-19: a randomized controlled study. *Complementary Therapies in Clinical Practice* 2020;39:101166.

199 Herridge MS, Cheung AM, Tansey CM, *et al*. One-Year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 2003;348:683–93.

200 Hatch R, Young D, Barber V, *et al*. Anxiety, depression and post traumatic stress disorder after critical illness: a uk-wide prospective cohort study. *Crit Care* 2018;22:310.

201 Lam MH-B. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors. *Arch Intern Med* 2009;169:2142.

202 Wing YK, Leung CM. Mental health impact of severe acute respiratory syndrome: a prospective study. *Hong Kong Med J* 2012;18:24–7.

203 Morgul E, Bener A, Atak M, *et al*. COVID-19 pandemic and psychological fatigue in turkey. *Int J Soc Psychiatry* 2021;67:128–35.

204 Tessitore E, Handgraaf S, Poncet A, *et al*. Symptoms and quality of life at 1-year follow up of patients discharged after an acute covid-19 episode. *Swiss Med Wkly* 2021;151:Swiss Med Wkly. 2021;151:w30093.

205 Soares MN, Eggelbusch M, Naddaf E, *et al*. Skeletal muscle alterations in patients with acute covid-19 and post-acute sequelae of covid-19. *J Cachexia Sarcopenia Muscle* 2022;13:11–22.

206 Goërtz YMJ, Van Herck M, Delbressine JM, *et al*. Persistent symptoms 3 months after a SARS-cov-2 infection: the post-COVID-19 syndrome? *ERJ Open Res* 2020;6:1–10.

207 Carfì A, Bernabei R, Landi F, *et al*. Persistent symptoms in patients after acute COVID-19. *JAMA* 2020;324:603.

208 Dennis A, Wamil M, Alberts J, *et al*. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. *BMJ Open* 2021;11:e048391.

209 Gautam N, Goyal S, Qureshi H, *et al*. Medium-term outcome of severe to critically ill patients with SARS-cov-2 infection. *Clin Infect Dis* 2021.

210 Darley DR, Dore GJ, Byrne AL, *et al*. Limited recovery from post-acute sequelae of SARS-cov-2 at 8 months in a prospective cohort. *ERJ Open Res* 2021;7:00384-2021.

211 Roth A, Chan PS, Jonas W. Addressing the long covid crisis: integrative health and long covid. *Glob Adv Health Med* 2021;10:21649561211056596.

212 Asadi-Pooya AA, Akbari A, Emami A, *et al*. Risk factors associated with long COVID syndrome: A retrospective study. *Iran J Med Sci* 2021;46:428–36.

213 Chopra N, Chowdhury M, Singh AK, *et al*. Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India. *Drug Discov Ther* 2021;15:156–61.

214 Novak P, Mukerji SS, Alabsi HS, *et al*. Multisystem involvement in post-acute sequelae of coronavirus disease 19. *Ann Neurol* 2022;91:367–79.

215 Wong-Chew RM, Cabrera EXR, Valdez CAR, *et al*. Symptom cluster analysis of long COVID-19 in patients discharged from the temporary COVID-19 hospital in mexico city: A longitudinal study. *LIFE SCIENCES* [Preprint] 2021.

216 Sollini M, Kirienko M, Gelardi F, *et al*. State-Of-The-Art of fapi-pet imaging: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging* 2021;48:4396–414.

217 Vanichkachorn G, Newcomb R, Cowl CT, *et al*. Post-COVID-19 syndrome (long haul syndrome): description of a multidisciplinary clinic at mayo clinic and characteristics of the initial patient cohort. *Mayo Clin Proc* 2021;96:1782–91.

218 Kedor C, Freitag H, Meyer-Arndt L, *et al*. Chronic COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) following the first pandemic wave in germany – a first analysis of a prospective observational study. *Infectious Diseases (except HIV/AIDS)* [Preprint].

219 Chan JCK. Recovery pathway of post-SARS patients. *Thorax* 2005;60:361–2.